Abstract
Background and Aims : CVD is the leading cause of premature death in AS. EPCs that protect against atherosclerotic vascular damage are depleted in AS contributing to enhanced CV-risk. Therapeutic potential of augmenting EPCs to treat the heightened CV-risk of AS has not yet been explored. This study investigates the effect of rosuvastatin on EPC population, vascular endothelial dysfunction and inflammation (surrogates of atherosclerosis) in AS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
